{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:49:17Z","timestamp":1775461757370,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Joint Funds for the innovation of science and Technology\uff0cFujian province","award":["No.2021Y9038"],"award-info":[{"award-number":["No.2021Y9038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04894-2","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:35:21Z","timestamp":1765445721000},"page":"7405-7414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disproportionality analysis of adverse events associated with bimekizumab: a real-world study based on FDA Adverse Event Reporting System (FAERS) Database"],"prefix":"10.1007","volume":"399","author":[{"given":"Xiaojuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-6098","authenticated-orcid":false,"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2729","authenticated-orcid":false,"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"4894_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55:379\u2013390. https:\/\/doi.org\/10.1007\/s12016-018-8702-3","journal-title":"Clin Rev Allergy Immunol"},{"key":"4894_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaad.2024.02.039","volume":"91","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Armstrong A, Merola JF, Strober B, De Cuyper D, Peterson L, Davies O, Stark JL, Lebwohl M (2024) Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: analysis of phase 2\/3 randomized trials. J Am Acad Dermatol 91:72\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2024.02.039","journal-title":"J Am Acad Dermatol"},{"key":"4894_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, SCH\u00f6N MP (2015) Psoriasis. Lancet 386:983\u2013994. https:\/\/doi.org\/10.1016\/s0140-6736(14)61909-7","journal-title":"Lancet"},{"key":"4894_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.36849\/jdd.8246","volume":"23","author":"J Burshtein","year":"2024","unstructured":"Burshtein J, Shah M, Zakria D, Armstrong AW, Golant AK, Gottlieb AB, Weinberg JM, Kircik L, Han G, Langley RG, Neimann AL, Lebwohl M (2024) Safety of bimekizumab for plaque psoriasis: an expert consensus panel. J Drugs Dermatol 23:592\u2013599. https:\/\/doi.org\/10.36849\/jdd.8246","journal-title":"J Drugs Dermatol"},{"key":"4894_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3899\/jrheum.220310","volume":"50","author":"CB Campanholo","year":"2023","unstructured":"Campanholo CB, Maharaj AB, Corp N, Bell S, Costa L, De Vlam K, Gullick NJ, Khraishi M, Kishimoto M, Palmou-Fontana N, Reddy S, Scarpa R, Vega L, Duarte GV, Zisman D, VAN DER Windt DA, Duruoz MT, Ogdie A (2023) Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol 50:426\u2013432. https:\/\/doi.org\/10.3899\/jrheum.220310","journal-title":"J Rheumatol"},{"key":"4894_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14760584.2023.2256394","volume":"22","author":"J Campling","year":"2023","unstructured":"Campling J, Vyse A, Liu HH, Wright H, Slack M, Reinert RR, Drayson M, Richter A, Singh D, Barlow G, Kassianos G, Ellsbury G (2023) A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom. Expert Rev Vaccines 22:785\u2013800. https:\/\/doi.org\/10.1080\/14760584.2023.2256394","journal-title":"Expert Rev Vaccines"},{"key":"4894_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107966","volume":"196","author":"M Chen","year":"2024","unstructured":"Chen M, Huang Y, Jiang S, Ke C (2024) Safety assessment of KRAS (G12C) inhibitors based on the FDA adverse event reporting system (FAERS) database: a real-world pharmacovigilance study. Lung Cancer 196:107966. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107966","journal-title":"Lung Cancer"},{"key":"4894_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/1567201819666220418104042","volume":"20","author":"M Contaldo","year":"2023","unstructured":"Contaldo M, Di Stasio D, Romano A, Fiori F, Della Vella F, Rupe C, Lajolo C, Petruzzi M, Serpico R, Lucchese A (2023) Oral candidiasis and novel therapeutic strategies: antifungals, phytotherapy, probiotics, and photodynamic therapy. Curr Drug Deliv 20:441\u2013456. https:\/\/doi.org\/10.2174\/1567201819666220418104042","journal-title":"Curr Drug Deliv"},{"key":"4894_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111365","author":"V Eshwar","year":"2022","unstructured":"Eshwar V, Kamath A, Shastry R, Shenoy AK, Kamath P (2022) A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15111365","journal-title":"Pharmaceuticals (Basel)"},{"key":"4894_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/ptt.s514249","volume":"15","author":"Z Fratton","year":"2025","unstructured":"Fratton Z, Bighetti S, Bettolini L, Maione V, Arisi M, Buligan C, Stinco G, Errichetti E (2025) Real-world experience of bimekizumab in a cohort of 109 patients over 48 weeks and identification of predictive factors for an early super response and risk of adverse events. Psoriasis (Auckl) 15:145\u2013158. https:\/\/doi.org\/10.2147\/ptt.s514249","journal-title":"Psoriasis (Auckl)"},{"key":"4894_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S (2018) Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 77:523\u2013532. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212127","journal-title":"Ann Rheum Dis"},{"key":"4894_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, Okubo Y, Rosmarin D, Lebwohl M, Peterson L, Madden C, De Cuyper D, Davies O, THA\u00e7I D (2024) Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol 190:477\u2013485. https:\/\/doi.org\/10.1093\/bjd\/ljad429","journal-title":"Br J Dermatol"},{"key":"4894_CR13","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1111\/bjd.15610","volume":"177","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, VAN DER Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, Augustin M (2017) The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol 177:e4\u2013e7. https:\/\/doi.org\/10.1111\/bjd.15610","journal-title":"Br J Dermatol"},{"key":"4894_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang L, Guo T, Zalkikar JN, Tiwari RC (2014) A review of statistical methods for safety surveillance. Ther Innov Regul Sci 48:98\u2013108. https:\/\/doi.org\/10.1177\/2168479013514236","journal-title":"Ther Innov Regul Sci"},{"key":"4894_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/000542217","author":"YD Jeong","year":"2024","unstructured":"Jeong YD, Jo H, Cho H, Jang W, Park J, Lee S, Lee H, Lee K, Oh J, Wen X, Smith L, Yon DK (2024) Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study. Int Arch Allergy Immunol. https:\/\/doi.org\/10.1159\/000542217","journal-title":"Int Arch Allergy Immunol"},{"key":"4894_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10030420","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM (2022) A standardized dataset of a spontaneous adverse event reporting system. Healthcare. https:\/\/doi.org\/10.3390\/healthcare10030420","journal-title":"Healthcare"},{"key":"4894_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1159\/000540542","volume":"102","author":"Z Liu","year":"2024","unstructured":"Liu Z, Wu D, Ke C, Nian Q, Chen Y, Huang Y, Chen M (2024) Real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System database for asciminib. Oncology 102:1084\u20131096. https:\/\/doi.org\/10.1159\/000540542","journal-title":"Oncology"},{"key":"4894_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/ced\/llae400","volume":"50","author":"M Megna","year":"2025","unstructured":"Megna M, Orsini D, Assorgi C, Balato A, Balestri R, Bianchi L, Brianti P, Brunasso G, Buononato D, Burlando M, Cagni AE, Caldarola G, Cameli N, Campanati A, Campione E, Carrera CG, Carugno A, Chersi K, Costanzo A, Cusano F, D\u2019amico D, Dal Bello G, Dapavo P, Dattola A, De Simone C, Di Lernia V, Dini V, Errichetti E, Esposito M, Fargnoli MC, Fiorella CS, Foti A, Gaiani FM, Gargiulo L, Gatti A, Gisondi P, Giunta A, Ibba L, Lasagni C, Loconsole F, Maione V, Malagoli P, Marzano AV, Maurelli M, Mercuri SR, Michelerio A, Michelucci A, Morrone P, Mortato E, Narcisi A, Offidani A, Paolino G, Parodi A, Pellacani G, Quaglino P, Richetta AG, Romano F, Sena P, Trevisan G, Uzzauto MT, Venturini M, Potestio L (2025) The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol 50:858\u2013859. https:\/\/doi.org\/10.1093\/ced\/llae400","journal-title":"Clin Exp Dermatol"},{"key":"4894_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80:1029\u20131072. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057","journal-title":"J Am Acad Dermatol"},{"key":"4894_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2432932","volume":"36","author":"E Mortato","year":"2025","unstructured":"Mortato E, Artosi F, Borselli C, Compagnucci I, Rivieccio A, Lanna C, Lambiase S, Gaeta Shumak R, Loconsole F, Bianchi L, Campione E (2025) Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics. J Dermatolog Treat 36:2432932. https:\/\/doi.org\/10.1080\/09546634.2024.2432932","journal-title":"J Dermatolog Treat"},{"key":"4894_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40265-024-02026-3","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie T, Shirley M (2024) Bimekizumab: a review in psoriatic arthritis. Drugs 84:587\u2013598. https:\/\/doi.org\/10.1007\/s40265-024-02026-3","journal-title":"Drugs"},{"key":"4894_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41:545\u2013568. https:\/\/doi.org\/10.1016\/j.rdc.2015.07.001","journal-title":"Rheum Dis Clin North Am"},{"key":"4894_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2393376","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, Bettacchi A, Bianchelli T, Bianchi L, Buggiani G, Burlando M, Brunasso A, Caldarola G, Cameli N, Campanati A, Campione E, Carugno A, Chersi K, Conti A, Costanzo A, Cozzani E, Cuccia A, D\u2019amico D, Dal Bello G, Dall\u2019olio EG, Dapavo P, De Simone C, Di Brizzi EV, Di Cesare A, Dini V, Esposito M, Errichetti E, Fargnoli MC, Fiorella CS, Foti A, Fratton Z, Gaiani FM, Gisondi P, Giuffrida R, Giunta A, Guarneri C, Legori A, Loconsole F, Malagoli P, Narcisi A, Paolinelli M, Potestio L, Prignano F, Rech G, Rossi A, Skroza N, Trovato F, Venturini M, Richetta AG, Pellacani G, Dattola A (2024) Efficacy and safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat 35:2393376. https:\/\/doi.org\/10.1080\/09546634.2024.2393376","journal-title":"J Dermatolog Treat"},{"key":"4894_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A (2021) Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 385:142\u2013152. https:\/\/doi.org\/10.1056\/NEJMoa2102383","journal-title":"N Engl J Med"},{"key":"4894_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/14740338.2023.2218086","volume":"22","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M (2023) Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf 22:355\u2013362. https:\/\/doi.org\/10.1080\/14740338.2023.2218086","journal-title":"Expert Opin Drug Saf"},{"key":"4894_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.s365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789\u2013802. https:\/\/doi.org\/10.2147\/clep.s365513","journal-title":"Clin Epidemiol"},{"key":"4894_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, THA\u00e7I D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K (2023) Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol 89:486\u2013495. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063","journal-title":"J Am Acad Dermatol"},{"key":"4894_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","volume":"188","author":"D THA\u00e7I","year":"2023","unstructured":"THA\u00e7I D, Vender R, De Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, De Cuyper D, Kimball AB (2023) Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol 188:22\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljac021","journal-title":"Br J Dermatol"},{"key":"4894_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15952","volume":"35","author":"M Valenti","year":"2022","unstructured":"Valenti M, Gargiulo L, Ibba L, Pavia G, Narcisi A, Costanzo A (2022) Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther 35:e15952. https:\/\/doi.org\/10.1111\/dth.15952","journal-title":"Dermatol Ther"},{"key":"4894_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K (2021) Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med 385:130\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa2102388","journal-title":"N Engl J Med"},{"key":"4894_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5114\/pg.2022.116374","volume":"17","author":"D Wietrzykowska-Grishanovich","year":"2022","unstructured":"Wietrzykowska-Grishanovich D, Pleskacz M, Kempi\u0144ski R (2022) Inflammatory bowel disease induced by bimekizumab. Prz Gastroenterol 17:175\u2013176. https:\/\/doi.org\/10.5114\/pg.2022.116374","journal-title":"Prz Gastroenterol"},{"key":"4894_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jdv.14175","volume":"31","author":"JJ Wu","year":"2017","unstructured":"Wu JJ, Penfold RB, Primatesta P, Fox TK, Stewart C, Reddy SP, Egeberg A, Liu J, Simon G (2017) The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol 31:1168\u20131175. https:\/\/doi.org\/10.1111\/jdv.14175","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4894_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11201-w","volume":"23","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Ding Y, Shu Y, Chen J (2023) A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data. BMC Cancer 23:745. https:\/\/doi.org\/10.1186\/s12885-023-11201-w","journal-title":"BMC Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04894-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:51:55Z","timestamp":1775458315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04894-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4894"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04894-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study is a secondary analysis of publicly available summary statistics and requires no specific ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}